Trial Profile

Efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lisdexamfetamine (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Therapeutic Use
Acronyms Shire SCT
Sponsors Shire; Takeda

Most Recent Events

29 Jun 2021 Results (n=39) assessing data from second phase (treatment phase) published in the Journal of Clinical Psychiatry
29 Jun 2021 According to a NYU Langone Medical Center media release, data from this study were published in the Journal of Clinical Psychiatry online.
29 Jun 2021 Results presented in a NYU Langone Medical Center media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com